Halozyme Therapeutics, Inc. (HALO)
Nasdaq · Common stock · Biological Products, (no Diagnostic Substances)
As of Oct 21, 2:18 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
Follow HALO in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on HALO and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
HALO at a glance
Key statistics
$14.12B
Market capitalization
- Previous close
- $124.37
- Open
- $126.19
- Day range
- $122.87 – $126.19
- Volume
- 995.6K
- Average volume (30 sessions)
- 2.48M
- Shares outstanding
- 113.50M
- Price / earnings
- 34.1
- Earnings per share
- $3.64
- Price / book
- 98.3
- Price / sales
- 8.5
- Beta (1 year, vs SPY)
- 0.49
Where the price sits in its year
52-week range
97% of the range
- Below the 52-week high
- -1.4%
- Above the 52-week low
- +103.2%
Completed sessions through Oct 20, 2026
Technical snapshot
Above its 50-day and 200-day averages
- 20-day average
- $113.50+9.6%
- 50-day average
- $109.74+13.3%
- 200-day average
- $81.16+53.2%
In the band above 70 that convention calls overbought. Strong trends can stay there for weeks.
+13.5%
1 week
+11.6%
1 month
+59.8%
3 months
+84.8%
Year to date
+85.5%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with HALO
HALO on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on HALO.
See the plans →
Every planScreen names like HALO
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on HALO
Put HALO on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on HALO
See whether there is an open premium alert on HALO, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
HALO headlines
- Halozyme Therapeutics Projects Sustained Growth Well Into 2040
Benzinga · Jan 28, 2026
- A Glimpse Into The Expert Outlook On Halozyme Therapeutics Through 8 Analysts
Benzinga · Jun 4, 2024
SEC Form 4, most recent first
Insider filings
Torley Helen
−4.8K
PRESIDENT AND CEO, Director · Open-market sale
$520.34K · Oct 8, 2026
Torley Helen
+20.0K
PRESIDENT AND CEO, Director · Option exercise
$368.20K · Oct 6, 2026
Torley Helen
−6.0K
PRESIDENT AND CEO, Director · Open-market sale
$656.00K · Oct 6, 2026
Torley Helen
−3.1K
PRESIDENT AND CEO, Director · Open-market sale
$336.53K · Oct 8, 2026
Torley Helen
−8.6K
PRESIDENT AND CEO, Director · Open-market sale
$954.87K · Oct 7, 2026
Torley Helen
−11.9K
PRESIDENT AND CEO, Director · Open-market sale
$1.31M · Oct 8, 2026
Torley Helen
−20.0K
PRESIDENT AND CEO, Director · Option exercise
$368.20K · Oct 6, 2026
Torley Helen
−20.0K
PRESIDENT AND CEO, Director · Option exercise
$368.20K · Oct 8, 2026
About Halozyme Therapeutics, Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
- Exchange
- Nasdaq
- Security
- Common stock
- Industry
- Biological Products, (no Diagnostic Substances)
- Headquarters
- San Diego, CA
- Employees
- 423
- Listed since
- Mar 12, 2004
- Website
- halozyme.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.